(19)
(11) EP 1 765 848 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.04.2009 Bulletin 2009/16

(45) Mention of the grant of the patent:
21.01.2009 Bulletin 2009/04

(21) Application number: 05759142.2

(22) Date of filing: 04.07.2005
(51) International Patent Classification (IPC): 
C07J 73/00(2006.01)
(86) International application number:
PCT/EP2005/007190
(87) International publication number:
WO 2006/002966 (12.01.2006 Gazette 2006/02)

(54)

PROCESS FOR THE PREPARATION OF 4-AZASTEROIDS

VERFAHREN ZUR HERSTELLUNG VON 4-AZASTEROIDEN

PROCÉDÉ POUR LA PRÉPARATION DE 4-AZASTÉROIDES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
HR YU

(30) Priority: 05.07.2004 EP 04015746

(43) Date of publication of application:
28.03.2007 Bulletin 2007/13

(73) Proprietor: Lonza AG
4052 Basel (CH)

(72) Inventors:
  • BESSARD, Yves
    CH-3960 Sierre (CH)
  • KUO, David
    Short Hills, NJ 07078 (US)


(56) References cited: : 
WO-A-95/12398
   
  • RASMUSSON G H ET AL: "AZASTEROIDS AS INHIBITORS OF RAT PROSTATIC 5ALPHA-REDUCTASE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 27, no. 12, 1 December 1984 (1984-12-01), pages 1690-1701, XP002043194 ISSN: 0022-2623
  • RASMUSSON G H ET AL: "AZASTEROIDS: STRUCTURE-ACTIVITY RELATIONSHIPS FOR INHIBITION OF 5ALPHA-REDUCTASE AND OF ANDROGEN RECEPTOR BINDING" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 29, no. 11, 1 November 1986 (1986-11-01), pages 2298-2315, XP000568779 ISSN: 0022-2623
  • BRATOEFF E ET AL: "STEROIDAL ANTIANDROGENS AND 5ALPHA-REDUCTASE INHIBITORS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 12, December 1999 (1999-12), pages 1107-1123, XP000874719 ISSN: 0929-8673
  • ISHIBASHI, K. ET AL.: "Synthesis and testosterone 5 alpha-reductase inhibitory activity of 11-substituted 4-aza-5alpha-androstane compounds" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, 1996, XP002306058
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).